New biosimilar aims to offer cheaper psoriasis treatment

NCT ID NCT07254325

Ongoing Disease control Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 study compares a new biosimilar drug, CMAB015, to the approved psoriasis treatment Cosentyx (secukinumab). The trial involves 114 healthy Chinese men who receive a single injection. Researchers will measure how the drug moves through the body, its safety, and whether the immune system reacts to it. This is an early step to see if the biosimilar is similar enough to Cosentyx to move into patient testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab (biosimilar CMAB015)
What this could lead to: If successful, this could lead to a more affordable version of Cosentyx for psoriasis, potentially lowering treatment costs.
What could go wrong: This is an early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug levels, not whether it works for psoriasis. The biosimilar may not perform the same as the original drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Shanghai Jiaotong University School of Medicine

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.